Delhi | 25°C (windy)

The Unending Saga: Majithia Drug Case Stalls Four Years On

  • Nishadil
  • February 04, 2026
  • 0 Comments
  • 3 minutes read
  • 9 Views
The Unending Saga: Majithia Drug Case Stalls Four Years On

Four Years, Multiple SITs, Still No Challan: The Curious Case of Punjab's High-Profile Drug Probe

Despite four years and numerous Special Investigation Teams, the high-profile drug case against SAD leader Bikram Singh Majithia remains without a chargesheet, raising questions about political will and justice in Punjab.

It’s a story that almost defies belief, truly. Imagine a high-profile drug case, one that has gripped Punjab’s attention for years, languishing without a formal chargesheet for a full four years. That’s precisely the perplexing situation we find ourselves in with the ongoing probe against senior Shiromani Akali Dal (SAD) leader, Bikram Singh Majithia.

The saga, if you can call it that, began way back on December 20, 2021. The Punjab State Crime Branch, under the glare of intense public scrutiny, registered a case against Majithia under the stringent Narcotic Drugs and Psychotropic Substances (NDPS) Act. At the time, it felt like a significant moment, a promise of accountability in the fight against drug trafficking, which has, sadly, plagued the state for far too long. Yet, here we are, well into 2024, and the case still awaits a crucial step: the filing of a challan, or chargesheet.

And it's not for lack of trying, at least on paper. Over these four years, the investigative efforts have seen no fewer than four different Special Investigation Teams (SITs) take the reins. Think about that for a moment. Four separate high-level police teams, each tasked with digging deep, gathering evidence, and bringing this case to a logical conclusion. From ADGP RN Dhoke's team in late 2021, through IG Mohnish Chawla’s stint in mid-2022, to ADGP Promod Ban leading two subsequent SITs in 2023 – and later ADGP Praveen Kumar Sinha – the baton has been passed, yet the finish line seems perpetually out of reach.

It’s almost as if the case has become a political hot potato, tossed between administrations. The initial FIR was lodged during the Congress government’s tenure. Then, the Aam Aadmi Party (AAP) swept into power, riding on a wave of anti-corruption sentiment and promises to tackle the drug menace head-on. Many expected swift action, a decisive move forward. But alas, even under the new guard, the wheels of justice in this particular matter have turned at an agonizingly slow pace, leading to widespread disappointment and, frankly, a lot of head-scratching.

Mr. Majithia himself secured anticipatory bail from the High Court, a decision later upheld by the Supreme Court in August 2022. The apex court's directive was clear: he must cooperate fully with the investigation. And while he has indeed appeared before the SITs for questioning, the fundamental issue remains unresolved. There's just no chargesheet. No official document detailing the evidence collected, the charges pressed, or outlining the path to prosecution.

Naturally, this prolonged delay has sparked serious concerns among legal experts, political commentators, and the general public alike. Senior lawyers are openly questioning the efficacy of the investigative process, pondering whether political machinations or perhaps a genuine lack of substantial, clinching evidence are at play. It’s hard not to wonder, isn't it? When a case of such magnitude remains in limbo for so long, the public's faith in the justice system can, understandably, start to waver.

Ultimately, the Majithia drug case stands as a stark reminder of the complexities and challenges inherent in high-stakes investigations, especially those with significant political undertones. Four years on, with multiple teams having scrutinised the details, the people of Punjab are still waiting for answers. And until that challan is finally filed, the shadow of doubt and the specter of unresolved justice will continue to loom large over this compelling, frustratingly protracted saga.

Disclaimer: This article was generated in part using artificial intelligence and may contain errors or omissions. The content is provided for informational purposes only and does not constitute professional advice. We makes no representations or warranties regarding its accuracy, completeness, or reliability. Readers are advised to verify the information independently before relying on